doi:10.3969/j.issn.1673-8640.2023.12.014

Abstract

CLC Number:

R446.1

Figures/Tables 6

References 6

[1]	ZWICKER J I, WANG T F, DEANGELO D J, et al. The prevention and management of asparaginase-related venous thromboembolism in adults:guidance from the SSC on hemostasis and malignancy of the ISTH[J]. J Thromb Haemost, 2020, 18(2):278-284. DOI URL
[2]	中国合格评定国家认可委员会. CNAS-GL03 能力验证样品均匀性和稳定性评价指南[S]. 北京: 中国合格评定国家认可委员会, 2006.
[3]	Reference materials-general and statistical principles for certification[S]. ISO GUIDE 35,ISO, 2006.
[4]	赖宇尧, 李桂珊, 王志明, 等. 抗Xa活性检测在抗凝药物监测中的应用[J]. 标记免疫分析与临床, 2020, 27(8):1444-1449.
[5]	高倩, 周文宾, 李臣宾, 等. 抗凝蛋白活性检测质控物的研制及初步评价[J]. 临床输血与检验, 2015, 17(3):193-197.
[6]	宋颖, 戴菁, 王青, 等. 采用冷冻干燥工艺制备地区性凝血因子室间调查品的初步研究[J]. 检验医学, 2015, 30(3):269-273.

浓度	均值/ （IU/mL）	s/（IU/mL）	CV/%	F值	P值
浓度1	0.62	0.01	1.43	0.69	0.70
浓度2	0.93	0.01	0.77	1.52	0.26

浓度	均值/ （IU/mL）	s/（IU/mL）	CV/%	F值	P值
浓度1	0.62	0.01	1.43	0.69	0.70
浓度2	0.93	0.01	0.77	1.52	0.26

浓度	均值/（IU/mL）	s/（IU/mL）	CV/%	F值	P值
浓度1	0.64	0.01	1.76	1.969	0.077
浓度2	0.94	0.01	1.22	1.927	0.083

浓度	均值/（IU/mL）	s/（IU/mL）	CV/%	F值	P值
浓度1	0.64	0.01	1.76	1.969	0.077
浓度2	0.94	0.01	1.22	1.927	0.083

组别	实验室数	均值		s		CV/%
组别	实验室数	浓度1	浓度2	浓度1	浓度2	浓度1	浓度2
不分组	14	0.55	0.99	0.07	0.10	11.97	9.85
A组	6	0.52	0.93	0.09	0.11	16.55	11.90
B组	6	0.58	1.06	0.04	0.05	6.47	4.30
C组	2	0.55	0.98	0.04	0.04	6.49	3.63

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 6

Related Articles 15

Recommended Articles

Metrics

[1]	DUAN Pengcang, DONG Ruifang, LIU Xiaoman, CAO Yang, WANG Ruoxi. Correlation between serum Trx2，P-tau and total magnetic resonance imaging load score and cognitive function in patients with cerebral small vessel disease [J]. Laboratory Medicine, 2024, 39(1): 1-6.
[2]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[3]	ZHANG Yang, ZHANG Dehe, TANG Shiyue, ZHANG Jun, WANG Jianming, CHEN Ling. Predictive value of soluble CD163 combined with Charlson index for esophageal variceal bleeding in patients with liver cirrhosis [J]. Laboratory Medicine, 2024, 39(1): 19-25.
[4]	LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer [J]. Laboratory Medicine, 2024, 39(1): 26-30.
[5]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[6]	ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease [J]. Laboratory Medicine, 2024, 39(1): 60-67.
[7]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[8]	LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12.
[9]	JIANG Haoqin, XU Qianqian, XU Liming, GUAN Ming. Homogenization management and practice of clinical blood and body fluid determinations [J]. Laboratory Medicine, 2024, 39(1): 95-99.
[10]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[11]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[12]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[13]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[14]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[15]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.